Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FATE THERAPEUTICS INC Director's Dealing 2018

Aug 7, 2018

34091_dirs_2018-08-07_5d807139-99f4-4e16-bfa5-f816198fbaae.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2018-07-31

Reporting Person: Valamehr Bahram (Chief Development Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 27958 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (right to buy) $11.03 2028-07-17 Common Stock (150000) Direct
Stock Option (right to buy) $6.55 2028-01-15 Common Stock (214800) Direct
Stock Option (right to buy) $2.73 2027-01-03 Common Stock (120000) Direct
Stock Option (right to buy) $2.90 2026-01-07 Common Stock (88080) Direct
Stock Option (right to buy) $4.84 2025-01-05 Common Stock (10704) Direct
Stock Option (right to buy) $6.62 2024-01-09 Common Stock (8500) Direct
Stock Option (right to buy) $7.87 2023-08-11 Common Stock (1536) Direct
Stock Option (right to buy) $1.37 2023-01-13 Common Stock (423) Direct
Stock Option (right to buy) $1.69 2021-03-11 Common Stock (3076) Direct
Stock Option (right to buy) $1.69 2020-02-10 Common Stock (1153) Direct

Footnotes

F1: Award of Restricted Stock Units, where 10,458 of the underlying shares are vested and 17,500 of the underlying shares vest on October 12, 2019. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.

F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 18, 2018 such that this option is fully exercisable on July 18, 2022.

F3: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022.

F4: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021.

F5: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020.

F6: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 5, 2015 such that this option is fully exercisable on January 5, 2019.

F7: This option is fully vested.